Living. Proof.

To you, it's giving your low-risk severe aortic stenosis patients a chance for superior* outcomes.

For him, it's setting the stage for an incredible encore.

Read the recently published ACC/AHA Guideline, which highlights TAVI for a treatment of valvular heart disease.

Read the new ESC Guidelines

and give your patients the benefits of TAVI

No one knows your symptomatic severe aortic stenosis (AS) patients like you do.

They count on your expertise to guide them. The path to the best chance at superior* outcomes for your low surgical risk patients.

* The PARTNER 3 TRIAL, SAPIEN 3 TAVI proven superior to surgery on the primary endpoint all-cause death, all stroke, and rehabilitation and multiple pre-specified secondary endpoints.

Severe aortic stenosis is progressive and can quickly become life-threatening

Even when your patients don’t acknowledge symptoms attributed to severe aortic stenosis, they trust you to identify the signs of severe aortic stenosis and they trust you to know when to act.2 Delays in referral for AVR treatment cost lives.3 A plan for aortic valve replacement as soon as symptoms occur gives severe AS patients the best possible chance at survival.

Free even your low-risk surgical patients from the burden of severe AS with TAVI

The PARTNER 3 Trial demonstrated unprecedented clinical outcomes with SAPIEN 3 TAVI, and is now proven superior* to surgery in low-risk symptomatic severe AS patients.4 So, you can consider your low-risk patients’ individual health and lifestyle needs, and guide them to a lower-risk treatment option.

* The PARTNER 3 TRIAL, SAPIEN 3 TAVI proven superior to surgery on the primary endpoint all-cause death, all stroke, and rehabilitation and multiple pre-specified secondary endpoints.

Give your patients the chance to get back to their lives faster

SAPIEN 3 TAVI is proven superior* across outcomes that matter most to your patients.4,5 TAVI patients recovered more rapidly than surgical patients, experiencing a better quality of life from baseline† and a greater feeling of well-being at 30 days.6

*The PARTNER 3 Trial, SAPIEN 3 TAVI proven superior to surgery on the primary endpoint all-cause death, all stroke, and rehospitalization‡ and multiple pre-specified secondary endpoints.
†Excludes multiplicity adjustment.
**Rehospitalization (valve-related or procedure-related and including heart failure).

Your severe AS patients trust you to guide them to the right treatment

Unlock the path to the best chance at superior* outcomes for your low surgical risk patients by guiding all your patients with valvular heart disease to a Multidisciplinary Heart Valve Team for timely treatment evaluation.

Collaborate with a Heart Team

*The PARTNER 3 TRIAL, SAPIEN 3 TAVI proven superior to surgery on the primary endpoint all-cause death, all stroke, and rehabilitation and multiple pre-specified secondary endpoints.

References:   1. Otto CM. Timing of aortic valve surgery. Heart. 2000;84:211-18. 2. 2014 AHA/ACC Guideline for the Management of Patients with Valvular Heart Disease. JACC 2014;63(22);e57-185. 3. Malaisrie SC, McDonald E, Kruse J, et al. Mortality while waiting for aortic valve replacement. Ann Thorac Surg. 2014;98:1564-71. 4. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380(18):1695-1705. 5. Leon MB, Mack MJ. PARTNER 3: transcatheter or surgical aortic valve replacement in low risk patients with aortic stenosis. Presented at ACC 2019; March 2019; New Orleans, LA. 6. The Partner 3 Trial Clinical Study Report; April 2019.